Cefepime Activity Against Serratia Species
Yes, cefepime is highly active against Serratia species and is an appropriate choice for treating Serratia infections. Cefepime demonstrates excellent in vitro activity against Serratia marcescens and other Serratia species, with activity superior to third-generation cephalosporins.
Microbiological Activity
The FDA drug label explicitly lists Serratia marcescens among the gram-negative bacteria for which at least 90% of isolates exhibit an in vitro MIC at or below the susceptible breakpoint for cefepime 1. This indicates robust activity against this organism.
Multiple surveillance studies confirm cefepime's potency against Serratia:
- In a large U.S. surveillance study of 9,777 gram-negative isolates, cefepime demonstrated >97% susceptibility against Serratia species, comparable only to imipenem 2
- An international study in Thailand showed cefepime had 92.3% activity against Serratia species, ranking second only to imipenem 3
- Cefepime maintains activity against Serratia strains that produce AmpC β-lactamases 4
Clinical Considerations for Serratia Infections
Serratia species possess chromosomal AmpC β-lactamases that are inducible, similar to Enterobacter and Citrobacter 5. This creates a critical advantage for cefepime:
- Cefepime has low potential for AmpC β-lactamase induction, even at low periplasmic concentrations 4
- Third-generation cephalosporins (ceftazidime, ceftriaxone) can induce AmpC production during therapy, leading to treatment failure
- Carbapenems remain highly active but should be reserved when possible to limit resistance pressure
Resistance Mechanisms to Monitor
While cefepime is generally effective, be aware that:
- Rare carbapenem-resistant Serratia strains producing SME-1 β-lactamase have been reported, though these remain susceptible to cefepime (MICs ≤0.25 mcg/mL) 6
- Recent data suggests that for ceftriaxone-susceptible Serratia bacteremia, narrower spectrum agents may be adequate, though cefepime remains appropriate 7
Recommended Approach
For empiric therapy of suspected or confirmed Serratia infections:
- Use cefepime 2g IV every 8-12 hours as first-line therapy 8, 9
- Consider combination with an aminoglycoside for severe infections or bacteremia until susceptibilities are known 9
- Reserve carbapenems (imipenem, meropenem) for documented resistance or critically ill patients 10
Once susceptibilities are available:
- If susceptible to ceftriaxone/ceftazidime, de-escalation may be considered for less severe infections 7
- For serious infections (bacteremia, pneumonia), continue cefepime or carbapenem to minimize risk of AmpC-mediated resistance emergence 5
Common Pitfall
Do not use third-generation cephalosporins alone for serious Serratia infections, even if initially susceptible, due to the risk of inducing AmpC β-lactamase production during therapy. Cefepime's stability against AmpC enzymes makes it the preferred cephalosporin choice 5, 4.